19-Nor C3,3-Disubstituted C21-Pyrazolyl Steroids for GABA Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing neuroactive steroids, such as progesterone, are not consistently effective in treating conditions related to brain excitability, including premenstrual syndrome, postnatal depression, and catamenial epilepsy, due to lack of dose-response relationship and potential side effects.
Innovation Solution
Development of 19-nor C3,3-disubstituted C21-pyrazolyl steroids with improved pharmacokinetic properties, oral bioavailability, and reduced metabolic pathways, acting as GABA modulators to regulate brain excitability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing neuroactive steroids such as progesterone are used to treat CNS-related disorders, then some therapeutic effect is achieved, but the treatment is not consistently effective due to lack of dose-response relationship and potential side effects
Solution Approach 1:
The patent modifies the chemical structure of existing neuroactive steroids by introducing specific substitutions at the C3 position (such as hydroxy, alkoxy, or halo groups) and varying substituents at C21 position. These parameter changes in molecular structure create a series of analogs with different potencies and pharmacokinetic properties, enabling the development of compounds with consistent dose-response relationships and improved therapeutic reliability for treating CNS-related disorders.
2Object-affected harmful factors
If progesterone and its metabolites are administered to treat conditions related to brain excitability, then some therapeutic benefits are achieved, but side effects and inconsistent efficacy limit their clinical utility
Solution Approach 1:
The patent introduces specific local modifications to the steroid molecule, particularly at the C3 position with various substituents (hydroxy, alkoxy, halo groups) and at the C21 position. These localized structural changes allow optimization of the compound's interaction with GABA receptors while reducing metabolism and side effects, thereby improving therapeutic consistency without compromising safety.
3Ease of manufacture
If 19-nor C3,3-disubstituted C21-pyrazolyl steroids are developed with improved pharmacokinetic properties, then oral bioavailability and reduced metabolic pathways are achieved, but the complexity of compound design and synthesis increases
Solution Approach 1:
The patent divides the modification strategy into distinct segments: (1) removal of the C19 angular methyl group to create the 19-nor structure, (2) disubstitution at the C3 position with specific groups, and (3) substitution at the C21 position with pyrazolyl or other groups. This segmented approach to molecular design allows systematic optimization of pharmacokinetic properties while managing synthetic complexity through modular structure-building.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel steroids effectively modulate GABA receptors, providing therapeutic benefits for CNS-related disorders such as sleep disorders, mood disorders, and epilepsy, with enhanced safety and efficacy profiles.
Implementation Method 1
GABA interacts with its recognition site on the GRC to facilitate the flow of chloride ions down an electrochemical gradient of the GRC into the cell. An intracellular increase in the levels of this anion causeshyperpolarization of the transmembrane potential, rendering the neuron less susceptible to excitatory inputs
Implementation Method 2
GABA regulates the excitability of individual neurons by regulating the conductance of chloride ions across the neuronal membrane
Data Source
AI summary
Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I):and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.